MMP9 Variant rs17576 Linked to Breast Cancer Susceptibility in Egyptian Women, Small Study Finds

A single-letter change in MMP9 tied to higher breast cancer odds
The rs17576 G allele appeared in 52.5% of patients versus 41.2% of controls in a 240-woman Egyptian study.
Mark

So what is the headline here? One variant, one gene, higher breast cancer odds?

Mimi

Yes. The rs17576 variant in MMP9. Women with the G/G genotype had about 2.5 times the odds of breast cancer compared with the reference genotype, and the G allele was more common in patients, 52.5 percent versus 41.2 percent.

Mark

And the second variant they tested?

Mimi

rs3787268 showed no independent association. It's an intronic variant, so that's a useful negative result.

Luke

Before we get excited, the sample is 120 cases and 120 controls. That's small for a genetic association study.

Mimi

True, and the authors say as much. It's one population, Egyptian women, and they call for larger, ethnically diverse cohorts.

Mark

Why does MMP9 make biological sense as a suspect?

Mimi

It remodels the matrix around cells and has been tied to tumor invasion and metastasis. The expression analyses also showed higher MMP9 in breast cancer tissue, linked to progression.

Luke

Careful, though. The protein destabilization figure, ΔΔG of −0.34 kcal/mol, is a computational prediction, not a lab measurement. Same with the eQTL and pathway findings.

Mark

So the bioinformatics supports a story but doesn't prove it.

Luke

Right. Nobody has shown yet that the variant changes MMP9 behavior in these women's tissue. That's what the functional studies are for.

Mimi

And for now it's about susceptibility, not diagnosis or treatment. Nothing here is ready for the clinic.

  • A single genetic letter in MMP9 is linked to roughly double the odds of breast cancer in the women studied.
  • The G version of the variant turned up in 52.5 percent of patients against 41.2 percent of healthy controls.
  • Computer predictions suggest the altered protein may be less stable and more active in breast tumors.
  • The study covers only one population of 240 women, so researchers are calling for larger, more diverse replication and lab tests before any clinical use.

In a study of 240 Egyptian women, researchers found that a single-letter change in the MMP9 gene, a protein that helps reshape the scaffolding around cells, appears more often among women with breast cancer than among healthy peers matched for age. The finding joins a long human effort to understand why some bodies are more vulnerable than others, reading inherited differences as clues rather than verdicts. For now it stands as a careful lead, awaiting larger and more diverse populations and laboratory confirmation before it can speak to anyone's care.

A study of 240 Egyptian women has tied a single-letter change in the MMP9 gene to a higher likelihood of breast cancer. Researchers compared 120 women with the disease against 120 healthy women of similar age, examining two variants of the gene.

MMP9 helps remodel the extracellular matrix, the structure surrounding cells, and has previously been implicated in tumor invasion and spread. The team genotyped every participant and applied statistical models to see how inherited combinations of variants related to disease risk.

The main variant, rs17576, showed a clear pattern. Women carrying the A/G genotype had about 2.3 times the odds of breast cancer, and those with G/G had about 2.5 times the odds. The G version appeared in 52.5 percent of patients but 41.2 percent of controls. The second variant, rs3787268, showed no independent link.

Computational analyses suggested rs17576 may destabilize the MMP9 protein and that the gene is more active in breast cancer tissue, where higher activity tracks with disease progression.

The authors are measured in their conclusions. Because only one population was studied, they urge caution. The next steps are replication in larger, ethnically diverse groups and laboratory work to confirm how the variant actually changes MMP9. Until then, the finding remains a promising lead rather than a clinical tool.

A study of 240 Egyptian women has tied a single-letter change in a gene called MMP9 to a higher likelihood of having breast cancer. The work compared 120 women with breast cancer against 120 healthy women matched to them by age, and it looked at two variants in the gene, known as rs17576 and rs3787268.

MMP9, short for matrix metalloproteinase-9, helps remodel the extracellular matrix, the scaffolding that surrounds cells. It has been implicated in tumor invasion and metastasis in several cancers, breast cancer among them. The researchers set out to see whether common variations in the gene's sequence might shape who develops the disease.

To find out, they genotyped every participant for both variants using TaqMan allelic discrimination assays. They then applied logistic regression models to test how genotypes, alleles and haplotypes, meaning combinations of variants inherited together, related to breast cancer susceptibility.

The result for rs17576, a missense variant that alters the protein's amino acid sequence, was clear in the statistics. Women carrying the A/G genotype had an odds ratio of 2.31 for breast cancer (95% confidence interval 1.24 to 4.29, p = 0.007). Those with G/G had an odds ratio of 2.46 (95% CI 1.16 to 5.22, p = 0.017). At the level of single alleles, the G version appeared in 52.5 percent of patients but 41.2 percent of controls, an odds ratio of 1.57 (95% CI 1.10 to 2.26, p = 0.013).

The second variant, rs3787268, sits within an intron, a stretch of the gene that does not code for protein. It showed no independent association with breast cancer susceptibility.

The team also ran a battery of computational analyses using GEPIA2, GTEx, TNMplot, muTarget, STRING, I-Mutant and 3DSNP. These tools examine gene expression patterns, expression quantitative trait loci (eQTL effects, where a variant is linked to changes in how much a gene is expressed), protein stability and likely molecular interactions. The predictions suggested rs17576 may affect MMP9's function and regulation. They included a predicted destabilization of the protein, with a ΔΔG of −0.34 kcal/mol, eQTL effects in breast tissue, and possible involvement in tumor-related molecular pathways. The expression data also pointed to higher MMP9 activity in breast cancer tissue, associated with disease progression.

The authors are careful about what this adds up to. They say the findings suggest rs17576 may contribute to breast cancer susceptibility in Egyptian women. Because only one population was studied, they ask that the results be read cautiously.

What comes next is replication: larger and ethnically diverse cohorts, plus functional laboratory work to test whether the variant actually changes how MMP9 behaves. Until then, the finding is a lead rather than a clinical tool.

Given the single-population design, the results should be interpreted cautiously and require validation in larger, ethnically diverse cohorts together with functional investigations.
— Study authors
Envie de l'histoire complète ? Lire l'original sur Nature ↗
Nous contacter FAQ